Transfer of three transcription factors via a lentiviral vector ameliorates spatial learning and memory impairment in a mouse model of Alzheimer's disease

Gene

Volumn 587, Issue 1, 2016, Pages 59-63

  Chen, Pin ^a   Yan, Qing ^c   Wang, Songtao ^c   Wang, Cunzu ^a   Zhao, Peng ^b,c  

^a NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

^b Jiangsu Shengze Hospital   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Gene therapy; Lentiviral ABN gene delivery; Neuroinflammatory; Neuroprotection; Transcription regulators; Water maze test

Indexed keywords

GROWTH FACTOR; LENTIVIRUS VECTOR; NEUROGENIN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRN2; TRANSCRIPTION FACTOR MASH1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HIPPOCAMPUS; INFLAMMATION; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPATIAL LEARNING; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; LENTIVIRINAE; MEMORY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HIPPOCAMPUS; LENTIVIRUS; MALE; MEMORY; MICE; MICE, INBRED C57BL; SPATIAL LEARNING; TRANSCRIPTION FACTORS;

EID: 84964687880     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2016.04.032     Document Type: Article

References (38)

1. Adlard P.A., Perreau V.M., Pop V., Cotman C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:4217-4221.
2. Cao L., Jiao X., Zuzga D.S., Liu Y., Fong D.M., Young D., During M.J. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 2004, 36:827-835.
3. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 2009, 66:300-305.
4. Denayer E., Ahmed T., Brems H., Van Woerden G., Borgesius N.Z., Callaerts-Vegh Z., Yoshimura A., Hartmann D., Elgersma Y., D'Hooge R., Legius E., Balschun D. Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J. Neurosci. 2008, 28:14443-14449.
5. Fuster-Matanzo A., Llorens-Martin M., Hernandez F., Avila J. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediat. Inflamm. 2013, 2013:260925.
6. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997, 20:154-159.
7. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
8. Heinrich C., Blum R., Gascon S., Masserdotti G., Tripathi P., Sanchez R., Tiedt S., Schroeder T., Gotz M., Berninger B. Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biol. 2010, 8.
9. Heinrich C., Gascon S., Masserdotti G., Lepier A., Sanchez R., Simon-Ebert T., Schroeder T., Gotz M., Berninger B. Generation of subtype-specific neurons from postnatal astroglia of the mouse cerebral cortex. Nat. Protoc. 2011, 6:214-228.
10. Heins N., Malatesta P., Cecconi F., Nakafuku M., Tucker K.L., Hack M.A., Chapouton P., Barde Y.A., Gotz M. Glial cells generate neurons: the role of the transcription factor Pax6. Nat. Neurosci. 2002, 5:308-315.
11. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
12. Kanninen K., Heikkinen R., Malm T., Rolova T., Kuhmonen S., Leinonen H., Yla-Herttuala S., Tanila H., Levonen A.L., Koistinaho M., Koistinaho J. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16505-16510.
13. Kaskie B., Storandt M. Visuospatial deficit in dementia of the Alzheimer type. Arch. Neurol. 1995, 52:422-425.
14. Kennington E. Gene therapy delivers an alternative approach to Alzheimer's disease. Nat. Rev. Drug Discov. 2009, 8:275.
15. Kiyota T., Ingraham K.L., Jacobsen M.T., Xiong H., Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E1339-E1348.
16. Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M., Copeland J.R., Dartigues J.F., Jagger C., Martinez-Lage J., Soininen H., Hofman A. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S4-S9.
17. Meng F., Chen S., Miao Q., Zhou K., Lao Q., Zhang X., Guo W., Jiao J. Induction of fibroblasts to neurons through adenoviral gene delivery. Cell Res. 2012, 22:436-440.
18. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
19. Munoz J.R., Stoutenger B.R., Robinson A.P., Spees J.L., Prockop D.J. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18171-18176.
20. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15:331-337.
21. Nash K.R., Lee D.C., Hunt J.B., Morganti J.M., Selenica M.L., Moran P., Reid P., Brownlow M., Guang-Yu Yang C., Savalia M., Gemma C., Bickford P.C., Gordon M.N., Morgan D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol. Aging 2013, 34:1540-1548.
22. Orellana D.I., Quintanilla R.A., Maccioni R.B. Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim. Biophys. Acta 2007, 1773:254-263.
23. Pang Z.P., Yang N., Vierbuchen T., Ostermeier A., Fuentes D.R., Yang T.Q., Citri A., Sebastiano V., Marro S., Sudhof T.C., Wernig M. Induction of human neuronal cells by defined transcription factors. Nature 2011, 476:220-223.
24. Parmar M., Jakobsson J. Turning skin into dopamine neurons. Cell Res. 2011, 21:1386-1387.
25. Pati S., Orsi S.A., Moore A.N., Dash P.K. Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory. Brain Res. 2009, 1256:85-91.
26. Qiao X., Cummins D.J., Paul S.M. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci. 2001, 14:474-482.
27. Quintanilla R.A., Orellana D.I., Gonzalez-Billault C., Maccioni R.B. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp. Cell Res. 2004, 295:245-257.
28. Ruiz de Almodovar C., Lambrechts D., Mazzone M., Carmeliet P. Role and therapeutic potential of VEGF in the nervous system. Physiol. Rev. 2009, 89:607-648.
29. Stefani M. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Prog. Neurobiol. 2012, 99:226-245.
30. Takata K., Kitamura Y. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: tangle formation, amyloid-beta, and microglia in Alzheimer's disease. J. Pharmacol. Sci. 2012, 118:331-337.
31. Takeuchi D., Sato N., Shimamura M., Kurinami H., Takeda S., Shinohara M., Suzuki S., Kojima M., Ogihara T., Morishita R. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008, 15:561-571.
32. Thies W., Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7:208-244.
33. Vierbuchen T., Wernig M. Direct lineage conversions: unnatural but useful?. Nat. Biotechnol. 2011, 29:892-907.
34. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Sudhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
35. Werner S., Unsicker K., von Bohlenund Halbach O. Fibroblast growth factor-2 deficiency causes defects in adult hippocampal neurogenesis, which are not rescued by exogenous fibroblast growth factor-2. J. Neurosci. Res. 2011, 89:1605-1617.
36. Woodbury M.E., Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J. NeuroImmune Pharmacol. 2014, 9:92-101.
37. Zambrano A., Otth C., Maccioni R.B., Concha I.I. IL-3 controls tau modifications and protects cortical neurons from neurodegeneration. Curr. Alzheimer Res. 2010, 7:615-624.
38. Zhou L., Li F., Xu H.B., Luo C.X., Wu H.Y., Zhu M.M., Lu W., Ji X., Zhou Q.G., Zhu D.Y. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat. Med. 2010, 16:1439-1443.